Phosphonic acid, P-[3-[[(2R,3R)-2-[(1R)-1-[3,5-bis(trifluoromethyl)phenyl]ethoxy]-3-(4-fluorophenyl)-4-morpholinyl]methyl]-2,5-dihydro-5-oxo-1H-1,2,4-triazol-1-yl]-
Uterine Cancer
Gynecologic Oncology AssociatesSmall moleculePhase 4 / ApprovedDormant
BB
68/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 54/ 100
- Competitive Position
- 89/ 100
Competitive context
47 Active assets in the Uterine Cancer cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Ferrous Fumarate Sunnybrook Health Sciences Centre | Phase 4 | BB |
(±)-1-BUTYL-2',6'-PIPECOLOXYLIDIDE MONOHYDROCHLORIDE University of California, Irvine | Phase 3 | B |
Nivolumab National Cancer Institute (NCI) | Phase 2 | B |
Atezolizumab Gradalis, Inc. | Phase 2 | B |
Bms-907351 National Cancer Institute (NCI) | Phase 2 | B |
View all 50 →
Same molecule, other indications
Phosphonic acid, P-[3-[[(2R,3R)-2-[(1R)-1-[3,5-bis(trifluoromethyl)phenyl]ethoxy]-3-(4-fluorophenyl)-4-morpholinyl]methyl]-2,5-dihydro-5-oxo-1H-1,2,4-triazol-1-yl]- is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →